Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Degludec (Tresiba) vs Insulin Lispro (Humalog)
An educational, source-based comparison of Insulin Degludec (Tresiba) and Insulin Lispro (Humalog) — how each peptide works, what it's researched for, and what to know before going deeper.
Ultra-long-acting basal insulin with >42-hour duration.
Insulin analog with a hexadecanedioic acid side chain at LysB29 that forms soluble multi-hexamers at the injection site, releasing monomers slowly for flat, prolonged action.
- Basal insulin therapy
- Flexible dosing schedules
- Reduced nocturnal hypoglycemia
- • FDA-approved.
- • Steady state reached after ~3 days.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Insulin Degludec (Tresiba) | DEVOTE trial | NEJM | 2017 | Cardiovascular safety vs glargine with lower severe hypoglycemia. |
| Insulin Lispro (Humalog) | Lispro pharmacokinetics vs regular insulin | Diabetes | 1994 | Faster onset and shorter duration improved postprandial control. |
Side-effect & safety grid
- FDA-approved.
- Steady state reached after ~3 days.
- FDA-approved.
- Hypoglycemia risk if meal delayed or skipped.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Insulin Degludec (Tresiba) vs Insulin Lispro (Humalog) — Key differences
- Class: Insulin Degludec (Tresiba) is classified as Insulin Analog · Endocrine, while Insulin Lispro (Humalog) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Degludec (Tresiba) — basal insulin therapy; Insulin Lispro (Humalog) — prandial coverage in t1d/t2d.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.
Insulin Lispro (Humalog) — Frequently Asked Questions
Insulin aspart vs lispro — are they equivalent?+
Insulin aspart (Novolog) and insulin lispro (Humalog) are both rapid-acting mealtime insulin analogues with very similar pharmacokinetics — onset ~10–15 minutes, peak ~1–2 hours, duration ~3–5 hours. Randomized crossover studies show broadly comparable HbA1c reduction, postprandial glucose control, and hypoglycemia rates when used equivalently in basal-bolus regimens. Choice is often driven by insurance coverage and delivery-device preference (pen vs pump compatibility).
Humalog vs Novolog — is there a clinical difference?+
In head-to-head comparisons the two rapid-acting analogues perform similarly on postprandial glucose excursion and rates of severe hypoglycemia. Small differences in absorption kinetics exist but rarely change clinical outcomes. Most guidelines treat them as clinically interchangeable within rapid-acting analogue insulin therapy.